{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"28.4","upperLimit":"52.9","value":"35.1"},{"groupId":"OG001","lowerLimit":"20.1","upperLimit":"37.1","value":"28.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"description":"Duration of response (calculated for responders only) is defined as time from the initial documented response (partial response or better) to confirmed disease progression, based on IMWG criteria assessed by the Independent Response Adjudication Committee.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 4 mg pomalidomide administered by mouth on Days 1-21 of each 28-day treatment cycle and 40 mg dexamethasone (participants \\> 75 years of age received 20 mg dexamethasone) administered by mouth once per day on Days 1, 8, 15, and 22 of a 28-day cycle until disease progression.","id":"OG000","title":"Pomalidomide Plus Low-Dose Dexamethasone"},{"description":"Participants received 40 mg dexamethasone (participants \\> 75 years of age received 20 mg dexamethasone) administered by mouth once per day on Days 1 through 4, 9 through 12, and 17 through 20 of a 28-day cycle until disease progression.","id":"OG001","title":"High-Dose Dexamethasone"}],"paramType":"MEDIAN","populationDescription":"Intent-to-treat responder population","reportingStatus":"POSTED","timeFrame":"From randomization until the data cut-off date of 01 March 2013. Maximum time on follow-up was 93 weeks.","title":"Duration of Response","type":"SECONDARY","unitOfMeasure":"weeks"}